Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon1 and 2 bp deletion in exon1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-CD58, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD58 also known as lymphocyte function-associated antigen 3 (LFA-3) is a glycoprotein with a molecular mass of approximately 60 kDa. It is present on the surface of various cell types including antigen-presenting cells epithelial cells and some other leukocytes. This protein serves as a ligand for CD2 which is expressed on T cells and natural killer cells. Through its interaction with CD2 CD58 mediates cell adhesion and plays a role in immunological synapse formation which is essential for effective immune responses.
Biological function summary
Lymphocyte function-associated antigen 3 acts as a significant participant in the immune system. It plays a role in T cell activation and facilitates interactions between T cells and antigen-presenting cells. CD58 forms part of a complex network of cell surface proteins that enhances immune surveillance and response. Its role highlights its importance in adaptive immunity by promoting cell-to-cell communication and activation.
Pathways
CD58 participates in the cell adhesion pathways. It interacts closely with CD2 which is involved in the activation and signaling of T cells. Through this interaction CD58 plays roles in pathways like T cell receptor signaling and immune response. It enhances cell-cell adhesion helping T cells maintain their position during immune surveillance and activation.
CD58 relates to conditions such as autoimmune diseases and certain cancers. In autoimmune disorders aberrant expression or function of CD58 may contribute to inappropriate immune activation leading to tissue damage. In cancer CD58 alterations can affect tumor immune evasion influencing how the immune system recognizes and attacks cancer cells. In multiple sclerosis an autoimmune disease the interaction between CD58 and CD2 has been studied providing insights into its role in disease mechanisms.
